RT info:eu-repo/semantics/article
T1 Acute and Preventive Treatment of COVID-19-Related Headache: A Series of 100 Patients
A1 García Azorín, David
A1 García Ruiz, Claudia
A1 Sierra Mencía, Álvaro
A1 González Osorio, Yesica
A1 Recio García, Andrea
A1 González Celestino, Ana
A1 García Iglesias, Cristina
A1 Planchuelo Gómez, Álvaro
A1 Echavarría Íñiguez, Ana
A1 Guerrero Peral, Angel Luis
K1 Headache disorders
K1 COVID-19
K1 Drug therapy
K1 Amitriptyline
K1 Migraine
K1 Botulinum toxins
K1 Vaccine
AB To describe the need and effectiveness of acute and preventive medications in a series of 100 consecutive patients referred due to COVID-19-related headaches. Patients were aged 48.0 (standard deviation (SD): 12.4), 84% were female, and 56% had a prior history of headache. The most common headache phenotype was holocranial (63%), frontal (48%), pressing (75%), of moderate intensity (7 out of 10), and accompanied by photophobia (58%). Acute medication was required by 93%, with paracetamol (46%) being the most frequently used drug, followed by ibuprofen (44%). The drugs with the highest proportion of a 2 h pain-freedom response were dexketoprofen (58.8%), triptans (57.7%), and ibuprofen (54.3%). Preventive treatment was required by 75% of patients. The most frequently used drugs were amitriptyline (66%), anesthetic blockades (18%), and onabotulinumtoxinA (11%). The drugs with the highest 50% responder rate were amitriptyline (45.5%), mirtazapine (50%), and anesthetic blockades (38.9%). The highest 75% responder rate was experienced following onabotulinumtoxinA (18.2%). In conclusion, most patients required acute medication, with triptans and non-steroidal anti-inflammatory drugs achieving the best responses. Three-quarters of patients required preventive medication. The most frequently used drug was amitriptyline, which obtained the best results. In some treatment-resistant patients, anesthetic blockades and onabotulinumtoxinA were also beneficial.
PB MDPI
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/70635
UL https://uvadoc.uva.es/handle/10324/70635
LA eng
NO Life (Basel), 2024, vol. 14, n. 7, p. 910
DS UVaDOC
RD 28-nov-2024